New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 10, 2012
18:55 EDTJAZZJazz Pharmaceuticals presents data from Erwinaze safety trial
Jazz Pharmaceuticals announced that data from the largest safety trial to date of patients treated with Erwinaze have been presented at the American Society of Hematology Annual Meeting and Exposition. The poster presentation is based on results of a compassionate use protocol in patients who received Erwinaze as part of a multi-agent chemotherapeutic regimen for acute lymphoblastic leukemia who developed a hypersensitivity to E.coli-derived asparaginase. The poster summarizes the safety results in 940 patients at participating U.S. oncology treatment centers between February 2006 and November 2011, when Erwinaze was available under a compassionate use protocol prior to its approval by the FDA in November 2011. The trial includes additional follow up data that further describe the incidence of adverse events associated with Erwinaze treatment, which are consistent with the known safety profile of Erwinaze.
News For JAZZ From The Last 14 Days
Check below for free stories on JAZZ the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
July 29, 2014
07:48 EDTJAZZJazz Pharmaceuticals price target raised to $177 from $171 at Leerink
Leerink raised its price target for Jazz Pharmaceuticals shares to $177 citing an improved outlook for defibrotide. The firm keeps an Outperform rating on the stock.
July 28, 2014
11:36 EDTJAZZCANbridge Life Sciences and EUSA Pharma form agreement to commercialize Caphosol
CANbridge Life Sciences has entered into an exclusive partnership with EUSA Pharma, a Jazz Pharmaceuticals company, to commercialize CaphosolŪ in China. Under the terms of the agreement, CANbridge obtains exclusive rights to commercialize Caphosol in China, where over 3.5M new cancer cases are diagnosed each year, and there is little in the way of a standard adjunct therapy to treat oral mucositis. Caphosol is a prescription medical device, approved in the United States and European Union, designed to moisten, lubricate and clean the oral cavity including the mucosa of the mouth, tongue and oropharynx.
July 23, 2014
08:29 EDTJAZZJazz Pharmaceutical initiated with a Buy at Buckingham
Target $215.
08:10 EDTJAZZDeutsche Bank hosts an analyst Specialty Pharma/Industry conference call
Subscribe for More Information
July 22, 2014
16:09 EDTJAZZJazz Pharmaceuticals initiated with a Buy at Deutsche Bank
Subscribe for More Information
July 17, 2014
10:00 EDTJAZZOn The Fly: Analyst Initiation Summary
Subscribe for More Information
July 16, 2014
17:22 EDTJAZZJazz Pharmaceuticals initiated with a Neutral at SunTrust
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use